Navigation Links
Researchers engineer a new way to inhibit allergic reactions without side effects
Date:10/13/2011

Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.

The therapy centers on a special molecule the researchers designed, a heterobivalent ligand (HBL), which when introduced into a person's bloodstream can, in essence, out-compete allergens like egg or peanut proteins in their race to attach to mast cells, a type of white blood cell that is the source of type-I hypersensitivity (that is, allergy).

"Unlike most current treatments, this approach prevents allergic reactions from occurring in the first place" says Basar Bilgicer, assistant professor of Chemical and Biomolecular Engineering and Chemistry and Biochemistry and principal investigator in Notre Dame's Advanced Diagnostics & Therapeutics initiative.

Michael Handlogten, lead scientist on the paper and a graduate student in Dr. Bilgicer's group, explained that among the various chemical functionalities he analyzed to be used as the scaffold HBL synthesis, ethylene glycol, an FDA-approved molecule, proved to be the most promising.

Mast cells are part the human body's defense against parasites (such as tapeworms), and when working normally they are attracted to, attach to, and annihilate these pathogens. But type-I hypersensitivity occurs when the cells react to non-threatening substances. More common allergies are due to ambient stimulants, and an allergic response may range from a mild itch to life-threatening anaphylactic shock.

Tanyel Kiziltepe, a research professor in Advanced Diagnostics & Therapeutics, adds that "anaphylaxis can be caused by certain food allergens, insect stings, antibiotics, and some medicines, and we believe HBL has a very high potential to be developed as a preventative medication".

While many medicines treat allergies by weakening a person's entire immune system, this approach only disrupts the process whereby white blood cells bond with allergens in the first place.

"It also does not leave patients open to an increased risk for infections or the development of cancers," explains Bilgicer. "HBLs may be most useful in situations where it's not possible to speak to or gauge someone's sensitivity."

"For example, in an emergency, on a battlefield, or in a remote location, doctors may not be able to ask a patient about an allergy before administering penicillin. An engineered HBL could be given along with the medicine and perhaps prevent a deadly reaction from occurring."

In a normal allergic reaction, allergens bind to a white blood cell, or "mast" cell, and cause the release of inflammatory molecules. Researchers at Notre Dame have shown how non-allergenic molecules, known as heterobivalent ligands, can be designed to attach to mast cells first, preventing the allergic reaction in the first place. (Image above: Backbone alignment of IgG, IgE, and IgM antibody crystal structure, including residues of the conserved nucleotide binding pocket. Credit: B. Bilgier)


'/>"/>

Contact: Basar Bilgicer
bbilgicer@nd.edu
574-631-3411
University of Notre Dame
Source:Eurekalert

Related medicine news :

1. National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases
2. Researchers discover hidden genetic influence on cancer
3. Toronto researchers find first physical evidence bilingualism delays onset of Alzheimers symptoms
4. Researchers track number of doctors disciplined and why
5. UCLA researchers develop new way to screen for brain cancer stem cell killers
6. Researchers find race disparity in post-hospital arrival homicide deaths at trauma centers
7. Researchers Assess What Works Best to Prevent PTSD
8. Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients
9. Researchers question key quality measure for asthma
10. Researchers from Boston University receive grant to develop improved virus detection system
11. Researchers review studies on CCSVI-MS link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... Medic CE , a Career Step company, is sponsoring a live, 1-hour ... Journal of Emergency Medical Services (JEMS). The free webinar, to be held on Wednesday, ... Duckworth, LP, a career fire captain as well as founder and director of the ...
(Date:5/24/2017)... ... , ... If you are thinking of a visit to San Francisco , fall is ... perfect time to visit. , Business Architecture Associates is pleased to offer 5 days of ... a 4-½ day package for individuals, and as 4-½ day corporate package for up to ...
(Date:5/24/2017)... ... ... Rob Lowe is a sought after actor, and also serves as the host ... topics from all aspects of life, and a new segment is being developed on ... , Podiatry is essential to people’s overall well-being, and if viewers have feet problems, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve ... decision process. As a result, labels need to deliver simple, transparent and clear ...
(Date:5/24/2017)... MN (PRWEB) , ... May 24, 2017 , ... ... of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed ... now consists of a mix of domestic and rest of world (ROW) authorized ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... , May 4, 2017  A recent ... Control, Ultraviolet-C light as a means ... SmartUVC,s ability to reduce bioburden on anesthesia workstations. ... reduction on high-touch, complex medical equipment surfaces contaminated ... infections. "This study further validates the ...
(Date:5/4/2017)... Wash. , May 4, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media ("BioLife" or the "Company"), today announced that the ... after market close on Thursday, May 11, 2017, and ... live webcast at 1:30 p.m. PT that afternoon. Management ...
Breaking Medicine Technology: